ReCor Medical

Executive Summary

ReCor Medical has developed the Paradise Ultrasound Renal Denervation (uRDN) System, a minimally invasive device that uses ultrasound energy to disrupt renal nerves and lower blood pressure. The system received FDA approval in late 2023 for the treatment of uncontrolled or resistant hypertension, offering a novel alternative to lifelong medication. ReCor is now focused on commercial launch, building a sales infrastructure, and securing favorable reimbursement. The company's technology is supported by robust clinical data from the RADIANCE-HTN trials, demonstrating significant and durable blood pressure reductions. With hypertension affecting over 100 million adults in the US alone, and many patients remaining uncontrolled on medication, ReCor is well-positioned to capture a sizable market. However, adoption faces hurdles including physician training, procedure reimbursement, and competition from other renal denervation devices. Overall, ReCor's execution in the near term will be crucial to establishing market leadership.

Upcoming Catalysts (preview)

• Q4 2025CMS National Coverage Determination (NCD) for Renal Denervation70% success
• Q4 2025Presentation of one-year data from RADIANCE-II pivotal trial90% success
• Q2 2026Commercial partnership or distribution agreement for European expansion60% success